ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments
Executive Summary
Institute for Clinical and Economic Review plans to evaluate the cost effectiveness of gene therapy, CAR-T drugs and tissue-agnostic cancer drugs, among other treatments, in 2018.
You may also be interested in...
ICER’s 2019 Agenda Includes CAR-T Therapy, Drugs For Depression, Arthritis, AMD
Proposed list of topics for review in 2019 by the Institute for Clinical and Economic Review includes a total of 15 drugs but that could change as the year goes on.
$1M For Luxturna? ICER Says Big Discount Needed To Be Cost Effective
Luxturna, a one-time treatment for a rare inherited form of blindness, would not be cost-effective at the $1m price level that has been suggested as a possibility, based on ICER's thresholds. But the small patient population would keep it from triggering ICER's US budget spending threshold.
Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS
The Centers for Medicare and Medicaid Services will only pay for Kymriah if patients respond after one month. Novartis also pursuing similar contracts with private payers.